Related Experiment Video
Updated: Nov 15, 2025
Author Spotlight: Investigating Bacteriophage-Induced Immune Responses in Gnotobiotic Mice
Published on: January 26, 2024
Exploring Mucin as Adjunct to Phage Therapy
Amanda Carroll-Portillo1, Henry C Lin1,2
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA.
Abstract:
Conventional phage therapy using bacteriophages (phages) for specific targeting of pathogenic bacteria is not always useful as a therapeutic for gastrointestinal (GI) dysfunction. Complex dysbiotic GI disorders such as small intestinal bowel overgrowth (SIBO), ulcerative colitis (UC), or Crohn's disease (CD) are even more difficult to treat as these conditions have shifts in multiple populations of bacteria within the microbiome. Such community-level structural changes in the gut microbiota may require an alternative to conventional phage therapy such as fecal virome transfer or a phage cocktail capable of targeting multiple bacterial species. Additionally, manipulation of the GI microenvironment may enhance beneficial bacteria-phage interactions during treatment. Mucin, produced along the entire length of the GI tract to protect the underlying mucosa, is a prominent contributor to the GI microenvironment and may facilitate bacteria-phage interactions in multiple ways, potentially serving as an adjunct during phage therapy. In this review, we will describe what is known about the role of mucin within the GI tract and how its facilitation of bacteria-phage interactions should be considered in any effort directed at optimizing effectiveness of a phage therapy for gastrointestinal dysbiosis.
Insights
Phage therapy for gut disorders faces challenges with complex microbial shifts. Mucin in the GI tract may enhance phage interactions, offering a potential adjunct for improving phage therapy effectiveness in dysbiosis.
Area of Science:
- Microbiology
- Gastroenterology
- Biotechnology
Background:
- Conventional bacteriophage (phage) therapy is limited for complex gastrointestinal (GI) dysbiosis, including small intestinal bowel overgrowth (SIBO), ulcerative colitis (UC), and Crohn's disease (CD).
- These conditions involve significant shifts in gut microbiota composition, necessitating alternative or enhanced therapeutic strategies beyond single-target phage treatments.
Purpose of the Study:
- To review the role of mucin in the GI tract.
- To explore how mucin facilitates bacteria-phage interactions.
- To consider mucin as an adjunct for optimizing phage therapy in GI dysbiosis.
Main Methods:
- Literature review on mucin's function in the GI tract.
- Analysis of existing research on bacteria-phage interactions within the gut.
- Synthesis of information regarding mucin's potential role in enhancing phage therapy efficacy.
Main Results:
- Mucin is a key component of the GI microenvironment, protecting the mucosa.
- Mucin can potentially facilitate interactions between bacteria and bacteriophages.
- Understanding mucin's role may lead to improved phage therapy strategies.
Conclusions:
- Current phage therapy approaches may be insufficient for complex GI dysbiosis.
- Mucin's interaction-facilitating properties present a novel avenue for enhancing phage therapy.
- Further research into mucin-bacteria-phage dynamics is crucial for optimizing GI dysbiosis treatments.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
08:51Profiling of Permethylated Mucin O-glycans Using Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry
Published on: June 20, 2025
Related Concept Videos
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
01:30Lytic Cycle of Bacteriophages
01:29Microorganisms in Medicine and Therapeutics
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...